Author

Ubenthira Patgunarajah

Institution: Mayo Clinic

Observed institutions: Cleveland Clinic, Mayo Clinic

OpenAlex ID: A5092083380

Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor

2024 · Dimitra Rafailia Bakaloudi, Rafee Talukder, et al. · Clinical Genitourinary Cancer · 12

Cardiovascular degeneration in Erdheim-Chester disease: prevalence, burden, and outcomes

2025 · Reema K. Tawfiq, Grant M. Spears, et al. · Blood Advances · 2

Effect of neutrophil to lymphocyte ratio (NLR) on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in real-world setting.

2024 · David Lynn, Scott Dawsey, et al. · Journal of Clinical Oncology · 2

Role of tumor mutational burden (TMB) and microsatellite instability (MSI) in patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitor (ICI).

2024 · Dimitra Rafailia Bakaloudi, Rafee Talukder, et al. · Journal of Clinical Oncology · 2

Genomic correlates of response and resistance to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.

2024 · Nikhil Pramod, Vladimir Makarov, et al. · Journal of Clinical Oncology · 2

Babesiosis-induced warm autoimmune hemolytic anemia, from infection to hemolysis: a case report

2025 · Jenna Davison, Jonah Kan, et al. · Journal of Medical Case Reports · 1

Effect of body mass index (BMI) on efficacy of immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) in real-world setting.

2024 · David Lynn, Scott Dawsey, et al. · Journal of Clinical Oncology · 1

Effect of antibiotic, proton pump inhibitor, H2 blocker, metformin and statin use on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting.

2024 · Charbel Hobeika, Scott Dawsey, et al. · Journal of Clinical Oncology · 1

Factors predictive of primary resistance (PrimRes) to immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial cancer (mUC).

2024 · Nikhil Pramod, Scott Dawsey, et al. · Journal of Clinical Oncology · 1

Effect of type of antibiotics (Abx) on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting.

2024 · Charbel Hobeika, Scott Dawsey, et al. · Journal of Clinical Oncology · 1

Characterizing immune-genomic signatures associated with response to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC).

2023 · Nikhil Pramod, Scott Dawsey, et al. · Journal of Clinical Oncology · 1

Mutational profiling links biologically relevant variants to multisystemic Rosai-Dorfman disease

2026 · Gordon J. Ruan, Steven Tessier, et al. · Blood Advances

KRAS mutations in histiocytic neoplasms: Mutation spectrum and response to MEK inhibition

2025 · Dongni Yi, Carla Isabel Borre, et al. · Blood

Deciphering immune-genomic markers of hyperprogression in patients (Pts) with metastatic urothelial cancer (mUC) treated with immune checkpoint inhibitors (ICIs).

2025 · Nikhil Pramod, Paul G. Pavicic, et al. · Journal of Clinical Oncology

Effect of body mass index (BMI) on efficacy of immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.

2024 · David Lynn, Charbel Hobeika, et al. · Journal of Clinical Oncology

The effect of antibiotic (Abx) use on immune checkpoint inhibitor (ICI) efficacy in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting.

2023 · Ubenthira Patgunarajah, Scott Dawsey, et al. · Journal of Clinical Oncology

Works count: 16

Citation count: 26

H-index: 2

I10-index: 1